Talis

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

Retrieved on: 
Tuesday, November 14, 2023

While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.

Key Points: 
  • While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.
  • The Company has engaged TD Cowen to act as a financial advisor in its review of strategic alternatives.
  • In connection with the evaluation of strategic alternatives and to preserve cash, Talis Biomedical is reducing its workforce by approximately 90 percent and consolidating operations to a single site in Chicago.
  • Due to its exploration of strategic alternatives, Talis Biomedical will not host a conference call to discuss third quarter results.

Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

Retrieved on: 
Wednesday, August 2, 2023

Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies.

Key Points: 
  • Dr. Lukowiak has more than 20 years of senior leadership experience in the clinical diagnostics industry at both publicly traded and privately held commercial-stage companies.
  • As a member of the executive leadership team, he will be responsible for leading the assay development, platform engineering, operations, regulatory and clinical affairs functions for Talis Biomedical.
  • “We are thrilled to welcome Andrew to our leadership team as we continue to develop the Talis One® test menu and plan to initiate clinical studies to support our pursuit of multiple 510(k) clearances,” said Rob Kelley,” chief executive officer at Talis Biomedical.
  • Prior to this, he was the chief executive officer at Millenium Health, a leading national toxicology laboratory specializing in clinical testing to support physicians in their treatment of substance use disorder.

New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu

Retrieved on: 
Thursday, July 27, 2023

REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS) today announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels. Results from these studies, presented in poster sessions at the 2023 IDSOG Annual Meeting in Denver, Colorado, support Talis Biomedical’s mission to advance health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.

Key Points: 
  • “The COVID-19 pandemic accelerated the development of numerous molecular point-of-care platforms to bring rapid respiratory testing closer to patients.
  • Unfortunately, very few are designed to effectively address the needs of women’s and sexual health,” said Rob Kelley, chief executive officer at Talis Biomedical.
  • In females, CT and TV were detected in 19/20 contrived vaginal swab samples at concentrations of 1 IFU/mL and 5 cells/mL, respectively.
  • LODs will be confirmed once a fully developed vulvovaginal candidiasis assay is integrated on the Talis One test cartridge.

TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 22, 2023

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO.

Key Points: 
  • Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Talis Biomedical Corporation (NASDAQ: TLIS) on behalf of long-term stockholders following a class action complaint that was filed against Talis on March 8, 2022 with a Class Period relating to stock purchases made pursuant to the Company’s February 2021 IPO.
  • Our investigation concerns whether the board of directors of Talis have breached their fiduciary duties to the company.
  • The complaint filed alleges that the Registration Statement was false and misleading and omitted to state material adverse facts.
  • There is no cost or obligation to you.

Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director

Retrieved on: 
Tuesday, May 23, 2023

Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director.

Key Points: 
  • Talis Bio also recently appointed Kim Popovits, who has served as a member of the board since March 2020, as its lead independent director.
  • She is the former chairman of the board, president and chief executive officer of Genomic Health.
  • Prior to joining Genomic Health in 2002, Ms. Popovits held multiple senior management roles of increasing responsibility at Genentech.
  • In addition to Talis Bio, she currently serves on the boards of several public and private healthcare companies.

Talis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of Shareholders

Retrieved on: 
Tuesday, May 9, 2023

The Talis One tests are being developed for respiratory infections, infections related to women's health, and sexually transmitted infections.

Key Points: 
  • The Talis One tests are being developed for respiratory infections, infections related to women's health, and sexually transmitted infections.
  • If you would like more information about our investigation of Talis Biomedical Corporation's misconduct, click here .
  • According to a class action complaint filed on behalf of Talis shareholders, Talis made false and misleading statements in connection with its February 2021 IPO.
  • What Now: Talis Biomedical Corporation (TLIS) shareholders have legal options.

Talis Biomedical Corporation (TLIS) Stockholders: Robbins LLP is Investigating TLIS on Behalf of Shareholders

Retrieved on: 
Tuesday, May 2, 2023

Shareholder rights law firm Robbins LLP is investigating Talis Biomedical Corporation (NASDAQ: TLIS) to determine whether certain Talis officers and directors violated securities laws and breached fiduciary duties to shareholders in connection with the Company’s February 2021 initial public offering ("IPO").

Key Points: 
  • Shareholder rights law firm Robbins LLP is investigating Talis Biomedical Corporation (NASDAQ: TLIS) to determine whether certain Talis officers and directors violated securities laws and breached fiduciary duties to shareholders in connection with the Company’s February 2021 initial public offering ("IPO").
  • The Talis One tests are being developed for respiratory infections, infections related to women's health, and sexually transmitted infections.
  • According to a class action complaint filed on behalf of Talis shareholders, Talis made false and misleading statements in connection with its February 2021 IPO.
  • What Now: Talis Biomedical Corporation (TLIS) shareholders have legal options.

Talis Biomedical Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022

REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the third quarter ended September 30, 2022.
  • To align resources with this new focus, Talis implemented a 35 percent reduction in force and additional cost-saving measures in the third quarter.
  • The company expects to start realizing the benefit of its restructuring plan in the fourth quarter of 2022.
  • Talis plans to provide progress updates as they are achieved or available and will not be hosting a conference call to discuss third quarter results.

Talis Biomedical Provides Business Update and Reports Second Quarter Financial Results

Retrieved on: 
Tuesday, August 2, 2022

In the second quarter, Talis continued to make progress on its ability to manufacture the Talis One system at scale.

Key Points: 
  • In the second quarter, Talis continued to make progress on its ability to manufacture the Talis One system at scale.
  • Revenue was $0.6 million for the second quarter of 2022, compared to $0.1 million for the same period in 2021.
  • Operating expenses were $26.5 million in the second quarter of 2022, compared to $64.5 million for the same period in 2021.
  • The company will host a live conference call and webcast to discuss the business update and financial results on Tuesday, August 2, 2022, at 4:30 PM ET / 1:30 PM PT.

Talis Biomedical Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Tuesday, March 15, 2022

Grant revenue was $0.9 million for the fourth quarter of 2021, as compared to $0.2 million for the same period in 2020.

Key Points: 
  • Grant revenue was $0.9 million for the fourth quarter of 2021, as compared to $0.2 million for the same period in 2020.
  • The revenue for the fourth quarter of 2021 was related to an NIH grant and a RADx contract with the NIH.
  • Operating expenses were $29.4 million in the fourth quarter of 2021, as compared to $44.4 million for the same period in 2020.
  • Net loss was $28.7 million for the fourth quarter of 2021, as compared to $44.2 million for the same period in 2020.